Обзорная статья

Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia

М. В. ЖуравлеваScientific Center for Examination of Medical Devices, Moscow, RussiaA. B. ProkofievScientific Center for Examination of Medical Devices, Moscow, RussiaS. Yu. SerebrovaScientific Center for Examination of Medical Devices, Moscow, RussiaN.S. VasyukovaFederal Scientific Center-all-Russian Research Skriabin and Kovalenko Institute of Experimental Veterinary Medicine the Russian Academy of Sciences, Moscow, RussiaE. Yu. DemchenkovaScientific Center for Examination of Medical Devices, Moscow, RussiaV. V. ArkhipovScientific Center for Examination of Medical Devices, Moscow, Russia

2020en

ABI

Аннотация

Chronic cerebral ischemia (CCI) is a common cerebrovascular syndrome, the development of which is associated with a high risk of increasing cognitive, behavioral, and motor disorders, and the formation of a patient's dependence on others. Timely start of treatment can slow down the course of the disease, make it more favorable. The review considers the possibility of using the domestic neuroprotector mexidol in patients with CCI. The results of a series of clinical studies on the use of ethylmethylhydroxypyridine succinate (mexidol) in patients with CCI are analyzed. The effectiveness of the drug in relieving cognitive, affective and motor disorders is noted. Information about the good tolerance of mexidol is presented.

Перевод пока недоступен

Идентификаторы

DOI: 10.17116/jnevro2020120061119

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar